{"id":"NCT00891176","sponsor":"GlaxoSmithKline","briefTitle":"Persistence of Antibodies at 3, 4 and 6 Years of Age After Vaccination With Meningococcal, Pneumococcal and Hib Vaccines","officialTitle":"Persistence of Antibodies After Full Vaccination Course With GSK Biologicals' Menitorix or MenC Conjugate Vaccine, Co-administered With DTPa or DTPa/Hib Containing Vaccine and Pneumococcal Conjugate Vaccine, in Children up to 6 Years of Age","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-05-14","primaryCompletion":"2012-11-21","completion":"2012-11-21","firstPosted":"2009-05-01","resultsPosted":"2010-12-23","lastUpdate":"2018-02-15"},"enrollment":582,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Neisseria Meningitidis","Haemophilus Influenzae Type b"],"interventions":[{"type":"BIOLOGICAL","name":"MenitorixTM","otherNames":[]},{"type":"BIOLOGICAL","name":"Pneumococcal conjugate vaccine GSK1024850A","otherNames":[]},{"type":"BIOLOGICAL","name":"PrevenarTM","otherNames":[]},{"type":"BIOLOGICAL","name":"MeningitecTM","otherNames":[]},{"type":"BIOLOGICAL","name":"NeisVac-CTM","otherNames":[]},{"type":"BIOLOGICAL","name":"InfanrixTM hexa","otherNames":[]},{"type":"BIOLOGICAL","name":"InfanrixTM penta","otherNames":[]},{"type":"BIOLOGICAL","name":"InfanrixTM IPV/Hib","otherNames":[]},{"type":"BIOLOGICAL","name":"InfanrixTM IPV","otherNames":[]}],"arms":[{"label":"Synflorix-Meningitec Group","type":"EXPERIMENTAL"},{"label":"Synflorix-NeisVac-C Group","type":"EXPERIMENTAL"},{"label":"Synflorix-Menitorix Group","type":"EXPERIMENTAL"},{"label":"Prevenar-Menitorix Group","type":"ACTIVE_COMPARATOR"}],"summary":"This protocol posting deals with objectives \\& outcome measures of an extension phase when subjects are aged 3, 4 and 6 years of age. The objectives \\& outcome measures of the primary phase are presented in a separate protocol posting (NCT number = NCT00334334). The objectives \\& outcome measures of the booster phase are presented in a separate protocol posting (NCT number = NCT00463437).\n\nThe purpose of this study is to evaluate the persistence of pneumococcal, meningococcal serogroup C, Hib and Hepatits B antibodies after booster vaccination, when the subjects are aged 3, 4 and 6 years. No vaccine will be administered during this persistence phase of the study.","primaryOutcome":{"measure":"Number of Subjects With Meningococcal Serogroup C Serum Bactericidal Titers Using Rabbit Complement (rSBA-MenC) Equal to or Above Cut-off Value","timeFrame":"At 3 years of age","effectByArm":[{"arm":"Synflorix-Meningitec Group","deltaMin":120,"sd":null},{"arm":"Synflorix-NeisVac-C Group","deltaMin":144,"sd":null},{"arm":"Synflorix-Menitorix Group","deltaMin":127,"sd":null},{"arm":"Prevenar-Menitorix Group","deltaMin":113,"sd":null}],"pValues":[]},"eligibility":{"minAge":"36 Months","sex":"ALL","healthyVolunteers":true,"inclusionCount":5,"exclusionCount":6},"locations":{"siteCount":28,"countries":["Germany","Poland","Spain"]},"refs":{"pmids":["27145999"],"seeAlso":["https://www.clinicalstudydatarequest.com"]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":144},"commonTop":[]}}